title: Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion.
abstract: The effect of hyperglycemia ( approximately 8 mmol/l) on splanchnic fatty acid oxidation and triacylglycerol (TG) secretion rates was investigated in five healthy men. U-13C-labeled fatty acids were infused to estimate fatty acid kinetics and oxidation across the splanchnic region, and in vivo labeled very low density lipoprotein (VLDL)-TG was infused to estimate TG secretion rate. Plasma fatty acid carbon enrichment and concentration were maintained constant by infusion of lipids and heparin in the hyperglycemia experiments. Fatty acid uptake by the splanchnic region was 1.4 +/- 0.2 and 2.2 +/- 0.9 micromol. kg-1. min-1 in the basal and clamp experiments, respectively, whereas fatty acid oxidation decreased from 0.4 +/- 0. 04 to 0.2 +/- 0.05 micromol. kg-1. min-1 (P < 0.05). Hepatic TG secretion increased from 0.35 +/- 0.07 micromol. kg-1. min-1 in the basal state to 0.53 +/- 0.11 micromol. kg-1. min-1 after 15 h of hyperglycemia (P < 0.05). Similarly, plasma VLDL-TG concentration increased from 0.28 +/- 0.06 to 0.43 +/- 0.05 mmol/l during the clamp (P < 0.05). In summary, hyperglycemia attenuates fatty acid oxidation in the splanchnic region in human volunteers, even when fatty acid availability is constant. This adaptation results in a significant increase in the VLDL-TG secretion rate and concentration in plasma.
authors.affiliation: Metabolism Unit, Shriners Burns Institute; and Departments of Surgery, Anesthesiology, and Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77550, USA.
authors.forename: L S
authors.initials: LS
authors.lastname: Sidossis
authors.forename: B
authors.initials: B
authors.lastname: Mittendorfer
authors.forename: E
authors.initials: E
authors.lastname: Walser
authors.forename: D
authors.initials: D
authors.lastname: Chinkes
authors.forename: R R
authors.initials: RR
authors.lastname: Wolfe
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002247:Carbon Isotopes; D005230:Fatty Acids, Nonesterified / Q000008:administration & dosage / Q000378:metabolism*; D015309:Glucose Clamp Technique; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology*; D007262:Infusions, Intravenous; D007700:Kinetics; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D008954:Models, Biological; D010084:Oxidation-Reduction; D010101:Oxygen Consumption; D011865:Radioisotope Dilution Technique; D012709:Serum Albumin / Q000378:metabolism; D013152:Splanchnic Circulation / Q000502:physiology*; D014280:Triglycerides / Q000378:metabolism*; D014316:Tritium
chemical_list: D001786:Blood Glucose; D002247:Carbon Isotopes; D005230:Fatty Acids, Nonesterified; D008079:Lipoproteins, VLDL; D012709:Serum Albumin; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D014316:Tritium; D006493:Heparin